Abstract Number: 1030 • 2014 ACR/ARHP Annual Meeting
ABT-122, a Novel Dual Variable Domain (DVD)-IgTM, Targeting TNF and IL-17, Inhibits Peripheral Blood Mononuclear Cell Production of GM-CSF and Decreases Lymphocyte Expression of CXCR4 in Healthy Subjects
Background/Purpose: TNF and IL-17 contribute to the pathogenesis of several inflammatory disorders and are known to synergistically induce chemokines and cytokines, including chemokine (C-X-C motif)…Abstract Number: 998 • 2014 ACR/ARHP Annual Meeting
β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10
Background/Purpose Splenic B cells from collagen-induced arthritis (CIA) mice react to a β2-adrenoceptor (AR) stimulus with increased IL-10 production and adoptive transfer of these cells…Abstract Number: 951 • 2014 ACR/ARHP Annual Meeting
Safety, Tolerability, and Functional Activity of ABT-122, a Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose Administration in Healthy Subjects
Background/Purpose: Several lines of evidence indicate that greater clinical efficacy and protection of joints may be possible in patients with RA by neutralizing TNF and…Abstract Number: 2876 • 2014 ACR/ARHP Annual Meeting
Interleukin-10 Receptor Blockade during Lcmv Infection Results in Macrophage Activation Syndrome-like Disease in Mice
Background/Purpose: Macrophage activation syndrome (MAS) is the rheumatic disease-associated member of a group of hyperinflammatory syndromes characterized by uncontrolled cytokine storm manifest as unremitting fevers,…Abstract Number: 947 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of NNC01140006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Background/Purpose A phase 2, randomised, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of NNC0114-0006 in patients with active rheumatoid arthritis…Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting
Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…Abstract Number: 665 • 2014 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies and damage tomultiple organs.…Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting
Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE
Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…Abstract Number: 322 • 2014 ACR/ARHP Annual Meeting
Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Background/Purpose: T helper 17 [TH17] cells and its production of TH17 cytokines IL-17A and IL-17F play a critical role in the pathogenesis of RA and…Abstract Number: 2168 • 2014 ACR/ARHP Annual Meeting
Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation
Background/Purpose: Many rheumatic diseases are driven by chronic, repeated activation of Toll-like receptors (TLR) causing the initiation and perpetuation of disease. However, TLR-activated innate immune…Abstract Number: 311 • 2014 ACR/ARHP Annual Meeting
Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome
Background/Purpose: MAS occurs frequently in patients with active systemic juvenile idiopathic arthritis(s-JIA) and because of the similarities with Haemophagocytic Lymphohistiocytosis (HLH) is classified among secondary…Abstract Number: 1291 • 2013 ACR/ARHP Annual Meeting
COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic
Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…Abstract Number: 1168 • 2013 ACR/ARHP Annual Meeting
Innate Immune Cell Production Of Interleukin-12 Drives CpG-Induced Macrophage Activation Syndrome
Background/Purpose: Hemophagocytic syndromes are caused by an uncontrolled systemic inflammatory response resulting in cytopenias, multisystem organ failure, and rapid death, often despite aggressive therapy. Macrophage…Abstract Number: 951 • 2013 ACR/ARHP Annual Meeting
The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF
Background/Purpose: Fibroblast-like synoviocytes (FLS) are targets of the pro-inflammatory IL-17 cytokines and a major source of inflammatory mediators in the inflamed synovium in rheumatoid arthritis…Abstract Number: 939 • 2013 ACR/ARHP Annual Meeting
Reduction Of Circulating Blood Neutrophils In Mice By Anti-IL-6R Alpha Monoclonal Antibody is Not Due To Apoptosis Or Blockade Of Neutrophil Differentiation
Background/Purpose: Blockade of IL-6/IL-6Rα signaling is associated with a reduction of circulating neutrophils in the blood of patients treated with anti-IL-6Rα mAb but the mechanism…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 12
- Next Page »